THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS
Launched by UNIVERSITY OF CAMPINAS, BRAZIL · Sep 13, 2014
Trial Information
Current as of May 27, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • head and neck cancer
- • anticancer treatment - cisplatin (80 to 100 mg/m²) plus radiotherapy
- • patients without previous treatment of head and neck cancer (surgery, chemotherapy and radiotherapy)
- Exclusion Criteria:
- • severe psychiatric diseases
- • impossibility of verbal communication
- • without caregivers or companions
About University Of Campinas, Brazil
The University of Campinas (Universidade Estadual de Campinas, UNICAMP) is a prestigious research institution located in Brazil, renowned for its commitment to advancing knowledge and innovation in the medical and scientific fields. With a strong emphasis on interdisciplinary collaboration, UNICAMP conducts cutting-edge clinical trials aimed at improving healthcare outcomes and developing novel therapeutic approaches. The university leverages its extensive resources, including state-of-the-art laboratories and a team of highly qualified researchers and clinicians, to contribute significantly to the global body of medical research while fostering education and training in clinical and translational sciences.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Campinas, São Paulo, Brazil
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials